CCL2 and type 2 diabetes mellitus: Another reduction was achieved in plasminogen activator inhibitor-1, a fibrinolysis inhibitor, monocyte chemoattractant protein-1 [85,87], implicated in the infiltration of monocytes/macrophages at the initiation of inflammation [88] and the monocyte-derived microparticles [85], which are released under inflammatory conditions and are usually elevated in patients with T2D [89].